EpSSG News

23 October 2019

SIOP 2019

SIOP

51-st Congress of the International Society of paediatric oncology
Lyon, France

Local Organizer Christophe Bergeron

The 51st Annual Congress of the International Society of Paediatric Oncology will take place October…
Read more
23 May 2019

EpSSG Spring Prague MEETING 2019

EPSSG Spring Meeting Prague 2019

Prague May 23-24 2019

Location: Prague, Czech Republic

Official EpSSG Spring Meeting 2019 within SIOP Europe Annual MeetingOur meeting this year will take…
Read more
04 April 2019

POSTDOCTORAL POSITION

POSTDOC

Deadline: 15 June 2019

INSTITUT CURIE, SIREDO ONCOLOGY CENTER
Paris, France

Read more
18 March 2019

Board Meeting in London

EpSSG Board meeting in Paris this October
The next Board meeting will be held in London and is hosted from Dr. Julia Chisholm. This meeting is…
Read more
07 February 2019

NEW EpSSG PAPER first of 2019!!

Indeterminate pulmonary nodules at diagnosis in rhabdomyosarcoma; Are they clinically significant? A report from the European paediatric Soft tissue sarcoma Study Group

January 31, 2019 the EpSSG study entitled 'Indeterminate pulmonary nodules at diagnosis in rhabdomyosarcoma; Are they clinically significant? A report from the European paediatric Soft tissue sarcoma Study Group' was published online in Journal of Clinical Oncology. In this study we assessed the clinical value of small lung nodules, not fulfilling the criteria for pulmonary metastases. This was an EpSSG radiology study, conducted in 15 larger centers in the United Kingdom, France, Italy and the Netherlands. We showed that small lung nodules are a frequently encountered diagnostic problem, occurring in over 20% of the patients with otherwise localized rhabdomyosarcoma. More importantly, this study showed that the presence of small lung nodules did not impact survival in patients with otherwise localized rhabdomyosarcoma, treated according to the RMS2005 protocol for localized disease. This study proves that patients with small lung nodules do not require additional chest radiotherapy and/or intensified chemotherapy. These results will be used in the upcoming EpSSG Frontline and Relapsed-RMS study.

Read more